These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8536776)

  • 1. Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
    Kaplan SA; Soldo KA; Olsson CA
    Eur Urol; 1995; 28(3):223-8. PubMed ID: 8536776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of dosing regimen on efficacy and safety of doxazosin in normotensive men with symptomatic prostatism: a pilot study.
    Kaplan SA; Soldo KA; Olsson CA
    Urology; 1994 Sep; 44(3):348-52. PubMed ID: 7521090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
    Kaplan SA; Te AE; Ikeguchi E; Santarosa RP
    Br J Urol; 1997 Dec; 80(6):875-9. PubMed ID: 9439400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Sunshine H
    J Urol; 1990 Dec; 144(6):1393-7; discussion 1397-8. PubMed ID: 1700152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
    Lepor H; Knapp-Maloney G; Wozniak-Petrofsky J
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):392-7. PubMed ID: 2477339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.
    Roehrborn CG; Oesterling JE; Auerbach S; Kaplan SA; Lloyd LK; Milam DE; Padley RJ
    Urology; 1996 Feb; 47(2):159-68. PubMed ID: 8607227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia.
    Tsujii T
    Int J Urol; 2000 Jun; 7(6):199-205. PubMed ID: 10843450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.
    Brawer MK; Adams G; Epstein H
    Arch Fam Med; 1993 Sep; 2(9):929-35. PubMed ID: 7509243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.
    de Mey C; Michel MC; McEwen J; Moreland T
    Eur Urol; 1998; 33(5):481-8. PubMed ID: 9643668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia.
    Kaplan SA; Meade-D'Alisera P; Quiñones S; Soldo KA
    Urology; 1995 Oct; 46(4):512-7. PubMed ID: 7571220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
    Lepor H
    Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
    Samli MM; Dincel C
    Urol Int; 2004; 73(2):125-9. PubMed ID: 15331896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.
    Andersen M; Dahlstrand C; Høye K
    Eur Urol; 2000 Oct; 38(4):400-9. PubMed ID: 11025377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of terazosin in the treatment of benign prostatic hyperplasia. A pilot study.
    Dunzendorfer U
    Arzneimittelforschung; 1989 Oct; 39(10):1289-91. PubMed ID: 2482025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
    Lepor H; Meretyk S; Knapp-Maloney G
    J Urol; 1992 Jun; 147(6):1554-7. PubMed ID: 1375659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH.
    Lepor H; Machi G
    Prostate; 1992; 20(2):89-95. PubMed ID: 1372430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.